# PT-141: Research Overview — LuvThy Peptide > A literature summary of PT-141 (bremelanotide), the lead Sexual & Reproductive Research peptide: MC4R mechanism, RECONNECT Phase 3 trial data, neuroimaging evidence, regulatory status and key cautions. Bremelanotide — a synthetic melanocortin agonist that acts on hypothalamic circuits governing sexual desire, with FDA approval for a narrow indication and an important boundary around everything else. ## The short version PT-141 is the research name for **bremelanotide**, a synthetic cyclic heptapeptide that activates melanocortin receptors in the brain — chiefly MC4R — in the hypothalamic and limbic circuits that govern sexual desire and arousal [7]. Unlike drugs that act on blood flow, PT-141 works centrally on the neural architecture of motivation. The regulatory picture matters here. Bremelanotide injection received FDA approval in June 2019 for one specific indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [5]. Two large Phase 3 trials (the RECONNECT studies, n=1267) demonstrated statistically significant improvements in sexual desire and distress over 24 weeks [3]. That is the approved use — for that population, with that diagnosis, under prescription. Everything else — use in men, use in postmenopausal women, performance enhancement — is off-label and, as a research chemical outside the pharmaceutical framework, unapproved. This page summarizes what was studied. It is not advice and lists no human dose. ## What it is PT-141 (bremelanotide) is a cyclic heptapeptide lactam analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge between the Asp and Lys side chains. It is a metabolite and structural relative of melanotan II, but with the C-terminal amide replaced by a carboxylic acid, a change that eliminates most of the tanning (melanogenic) activity while preserving melanocortin agonism. Synonyms in the literature include bremelanotide, PT 141, bremelanotide acetate, BMT, and cyclo-[Nle4-Asp5]-alpha-MSH(4-10). It is a synthetic research peptide and a prescription pharmaceutical (in its approved form); the research-chemical form sold outside that approval carries no regulatory quality guarantees. ## How it works PT-141 activates central melanocortin receptors, principally MC4R (and MC3R), concentrated in the hypothalamus and limbic system. By stimulating MC4R in hypothalamic circuits such as the medial preoptic area, it is thought to engage dopaminergic pathways governing sexual desire and arousal [7]. A key mechanistic finding from a 2022 fMRI study in 31 premenopausal women with HSDD confirmed this central action in humans: MC4R agonism enhanced amygdala-insula functional connectivity and cerebellar and supplementary-motor activity in response to erotic stimuli, with increased sexual desire lasting up to 24 hours [2]. The fMRI data provide neuroimaging-level evidence that the effect is a change in how the brain processes sexual information, not a peripheral vascular action. Importantly, an animal study in 2025 added nuance: in female Syrian hamsters, bremelanotide did not enhance sexual reward as measured by conditioned place preference, and did not change melanocortin-receptor mRNA in the mesolimbic (VTA-NAc) dopamine reward circuit [1]. This suggests the mechanism does not run entirely through the classical reward pathway — the picture of how it works at the circuit level is still being refined. ## What the research shows *Foundational animal pharmacology.* In female rats, PT-141 selectively increased appetitive solicitational sexual behaviors without affecting lordosis, pacing, or general motor activity — making it the first reported pharmacological agent acting specifically on appetitive female sexual behavior via central melanocortin systems [6]. Penile erections were produced in rats and nonhuman primates, and rapid dose-dependent erectile activity was demonstrated in men with erectile dysfunction in early Phase 2 work, along with hypothalamic neuronal activation (increased c-Fos) consistent with a central mechanism [7]. *Phase 3 human trials.* The RECONNECT program comprised two identical Phase 3 randomized, double-blind, placebo-controlled trials in 1267 premenopausal women with HSDD. Bremelanotide 1.75 mg subcutaneous as-needed produced statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and reduced desire-related distress (FSDS-DAO item 13 -0.33, P<.001) versus placebo over 24 weeks [3]. The most common adverse events were nausea, flushing, and headache. *Long-term extension.* A 52-week open-label extension enrolled 684 women. No new safety signals emerged; sexual-desire improvements were sustained. The most common drug-related treatment-emergent adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%), confirming nausea as the principal tolerability issue over time [4]. *Approved label pharmacokinetics.* The prescribing information specifies terminal half-life approximately 2.7 hours (range 1.9-4.0 h), volume of distribution 25.0 L, and a warning on transient blood-pressure increase; the label contraindicates use in uncontrolled hypertension or cardiovascular disease [5]. ## Reported effects, cautions & safety The Phase 3 and extension data establish a safety profile for the one approved indication. Several specific cautions run through the literature. **Cited cautions from the peer-reviewed record:** - *Approved for one population only.* Bremelanotide is FDA-approved for acquired, generalized HSDD in premenopausal women under prescription. Use in men, postmenopausal women, or for any performance-enhancement purpose is off-label at best, and as a research chemical sold outside pharmaceutical oversight, unregulated [5]. - *Transient blood-pressure increase.* The label carries a specific warning on this; contraindicated in uncontrolled hypertension or known cardiovascular disease [5]. - *Nausea is common.* Approximately 40% of women in the 52-week extension reported nausea as a drug-related event; it is the leading driver of discontinuation [4]. - *Hyperpigmentation.* Repeated frequent dosing can cause hyperpigmentation of the face, gums, and breasts via MC1R activation [5]. - *Research-chemical form is unregulated.* Material sold as "PT-141 research chemical" sits outside the pharmaceutical approval framework, with no oversight of identity, purity, or concentration [5]. - *PT-141 is not a PDE-5 inhibitor.* It does not act on vascular smooth muscle. It is also not a testosterone-raising agent; it does not act via the HPG axis [7]. - *Small-but-significant effect size.* Critical re-analyses (Spielmans 2021, 2024) note the Phase 3 effects on desire and distress are statistically significant but modest, and raise questions about clinical meaningfulness and outcome-measure selection [3]. **Community field reports — anecdotal, not clinical evidence:** The literature for PT-141 includes a meaningful body of real-world observation because it is FDA-approved and widely discussed in clinical and lay settings. Some themes that recur: - Many users describe a clear increase in sexual interest and spontaneous arousal in the hours after dosing, onset typically one to two hours in [3]. - Both men and women in research-use communities describe the effect as a shift in *motivation* — a sense of wanting — rather than a change in physical arousal in the peripheral sense. - Nausea and facial flushing are the most consistently reported side effects, often described as dose-related and transient [4]. - Some users describe no perceptible subjective effect despite the documented central mechanism; individual variability appears substantial. These field observations are anecdotal, not clinical evidence, and are kept separate from the cited findings above. No dose is stated or implied. ## Where it fits in sexual research PT-141 is the lead on this desk — the only compound here with a completed Phase 3 program and regulatory approval. That approval is narrow and specific: premenopausal women, one diagnosis, one approved route, under prescription. It is also the compound that most directly addresses the brain circuitry of desire, with neuroimaging data confirming a central mechanism in the target population [2]. Read alongside [kisspeptin](/kisspeptin) — which acts one level upstream, on the reproductive hormone axis itself — PT-141 illustrates what a clinically validated central sexual-desire agent looks like, and where its limits are. See the [comparison page](/compare) for the side-by-side. ![PT-141 hypothalamic melanocortin signaling abstract](/images/pt-141.webp) --- A clinician's-briefing digest of the sexual and reproductive research-peptide literature — citations sourced, never prescribed.